KRAS and colorectal carcinoma: For non-hypermutated samples, EO-CRC had a higher rate of WGD than LO-CRC (54% vs 38%, Fisher’s exact P = 0.0399), which is in line with our aforementioned data of a higher frequency of TP53 mutations and lower frequencies of APC and KRAS mutations in EO-CRC.